ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Atypical exanthems in children

Atypical exanthems in children
Literature review current through: Jan 2024.
This topic last updated: Jul 17, 2023.

INTRODUCTION — An "atypical exanthem" is an acute skin eruption that differs in appearance from classically described viral rashes such as measles, rubella, or erythema infectiosum. They are usually preceded or associated with nonspecific systemic symptoms, including low-grade fever, malaise, or upper respiratory or gastrointestinal tract infection.

Atypical exanthems are a common cause of pediatric urgent care visits. The most frequent cause is a viral infection, followed by drug reactions, and bacterial infections [1,2].

This section will review three uncommon diseases that present with an atypical rash: unilateral laterothoracic exanthem; coxsackievirus A6 hand, foot, and mouth disease; and papular-purpuric gloves and socks syndrome. Gianotti-Crosti syndrome, a papular eruption of childhood with acral distribution associated with viral infections is discussed separately [3]. (See "Gianotti-Crosti syndrome (papular acrodermatitis)".)

UNILATERAL LATEROTHORACIC EXANTHEM — Unilateral laterothoracic exanthem (ULE), also known as asymmetric periflexural exanthem of childhood, is a distinctive skin eruption that usually begins on one side of the trunk and then generalizes [4-7]. It typically affects children between one and five years of age but has also been reported in adults [8-11].

ULE occurs year round, with a peak during spring. The cause is unknown. Indirect evidence, such as patients' age, occurrence of small epidemics, seasonal distribution, association with upper respiratory tract infections, and spontaneous resolution, suggests a viral etiology [12-14]. However, microbiologic studies on throat, stool, blood, and skin samples from affected children have not identified a specific etiologic agent [15-17].

Clinical manifestations — The skin eruption typically begins on one side of the trunk and extends toward the axilla; less often, it starts in the inguinal crease or on an extremity (picture 1). The eruption is usually preceded by an episode of low-grade fever, upper respiratory tract infection, or gastroenteritis [16]. The eruption spreads centrifugally and may become bilateral, although unilateral predominance is maintained.

Early lesions may have a morbilliform appearance, sometimes with a surrounding pale halo. Over time, lesions tend to become more scaly or eczematous and occasionally develop a central dusky or gray color. Most patients experience pruritus, but it is usually mild.

Diagnosis and differential diagnosis — The diagnosis of ULE is clinical. Laboratory tests are not indicated. A skin biopsy is not necessary for the diagnosis. If performed, it shows a mild to moderate mononuclear interface dermatitis, with some necrotic keratinocytes, and a dermal lymphocytic infiltrate more pronounced around the sweat glands [16].

The differential diagnosis of ULE includes tinea corporis, allergic contact dermatitis, atopic dermatitis, psoriasis, lichen striatus, and other viral exanthems such as pityriasis rosea.

(See "Dermatophyte (tinea) infections", section on 'Tinea corporis'.)

(See "Allergic contact dermatitis in children".)

(See "Guttate psoriasis".)

(See "Lichen striatus".)

(See "Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis".)

(See "Pityriasis rosea".)

Treatment and prognosis — ULE is a self-limited condition; the eruption typically remits in two to five weeks with fine desquamation [8]. Treatment is symptomatic and includes bland emollients and antihistamines to control pruritus. Topical steroids do not alter the natural course of ULE and are generally not needed.

ERUPTIVE PSEUDOANGIOMATOSIS — Eruptive pseudoangiomatosis is a rare, asymptomatic exanthematous eruption characterized by the rapid appearance of small, angioma-like, erythematous papules [18-20]. It predominantly affects young children but has also been reported in adults [21-24]. The cause of eruptive pseudoangiomatosis is unknown. There are isolated reports of eruptive pseudoangiomatosis associated with viral infections (eg, echovirus 25 or 32, cytomegalovirus, adenovirus, Epstein-Barr virus, coxsackie B virus, severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]), insect bites, and acute lymphoblastic leukemia [25-33].

Clinical manifestations — Patients typically present with the acute eruption of numerous bright-red erythematous and telangiectatic papules 1.5 to 5 mm in diameter that blanch with pressure, disseminated mainly on the face and trunk (picture 2). Annular and arciform, erythematous lesions and lesions with a peripheral halo have also been described [30,34]. Systemic symptoms, including fever, diarrhea, or upper respiratory symptom are often present in children. Lesions persist for 2 to 15 days and then resolve spontaneously without sequelae.

Diagnosis — The diagnosis of eruptive pseudoangiomatosis is based upon the clinical presentation. If performed, a skin biopsy examination reveals a perivascular lymphocytic infiltrate in the papillary dermis and dilated blood vessels with swollen, hobnail-shaped endothelial cells [18,35].

Treatment and prognosis — No treatment is necessary. Lesions usually resolve spontaneously in one to two weeks.

ATYPICAL HAND, FOOT, AND MOUTH DISEASE — Hand, foot, and mouth disease (HFMD) is a common enteroviral illness typically affecting children younger than five years during the late summer and fall months. HFMD is usually caused by coxsackievirus A16 and typically presents with fever, deep-seated, small oval vesicles on the palms and soles, and painful vesicles and erosions on the buccal mucosa and tongue (picture 3A-D). (See "Hand, foot, and mouth disease and herpangina", section on 'Hand, foot, and mouth disease' and "Hand, foot, and mouth disease and herpangina".)

Epidemiology and transmission — Outbreaks of HFMD caused by coxsackievirus A6 and characterized by an atypical presentation have been reported in Asia and in Europe since 2008 and in the United States since 2011 [36-40]. Coxsackievirus A6 HFMD has also been reported in young adults [41]. In 2015, an outbreak of 53 cases of HFMD caused by coxsackievirus A6 was reported among basic military trainees in Texas [42].

HFMD is transmitted person-to-person via oral or respiratory route following contact with vesicle fluid, respiratory secretions, and feces, and initial viral replication takes place in the pharynx and intestine. Subsequent amplification within lymphoid tissue produces a viremia with distant multiorgan spread, including the skin. Hand washing and routine disinfection of surfaces help preventing spreading.

There is a single case report of atypical HFMD caused by Coxsackie B5 virus [43].

Clinical manifestations — Patients with coxsackievirus A6 HFMD present with fever and systemic symptoms as in typical HFMD, but usually have a more severe cutaneous involvement. Vesiculobullous lesions may involve the dorsum of hands and feet, calves, forearms, trunk, and neck (picture 4A-B) [37,44,45]. The involvement of the perioral area may be a clinical marker of A6 HFMD [45].

In children with atopic dermatitis, lesions tend to concentrate in areas previously or currently affected by the dermatitis, similar to eczema herpeticum ("eczema coxsackium") (picture 5) [44]. In young adults, the disease may present with erythematous papulovesicular lesions on the face, oral mucosa, extensor surfaces of the upper and lower extremities, and palms and soles; confluent, hemorrhagic and crusted lesions can also be seen on the extremities (picture 6) [42].

The course of the acute illness and the benign outcome are similar in classic and atypical HFMD. Systemic symptoms usually subside in a few days; the skin lesions resolve without scarring in days to weeks.

Onychomadesis (separation of the proximal nail plate from the nail matrix and nail bed) due to arrest of nail matrix growth is frequent and most often occurs three to eight weeks after the disease onset. It is usually asymptomatic, and the nails regrow normally within several months. (See "Overview of nail disorders", section on 'Transverse grooves (Beau lines)'.)

Diagnosis and differential diagnosis — The diagnosis of coxsackie A6 HFMD is based upon the clinical presentation and detection of the virus in the blister fluid by polymerase chain reaction (PCR). Although PCR can detect enteroviruses with a sensitivity of approximately 90 percent, it does not allow the serotype identification. Coxsackievirus A6 nucleotide sequencing can be performed on PCR positive specimens to confirm the diagnosis [44]. (See "Enterovirus and parechovirus infections: Clinical features, laboratory diagnosis, treatment, and prevention".)

A skin biopsy is usually not necessary. If performed, it reveals a spongiotic dermatitis with focal areas of interface dermatitis and subepidermal separation, edema of the papillary dermis, and a mixed dermal inflammatory infiltrate [44].

The differential diagnosis of atypical HFMD includes eczema herpeticum (picture 7A-B), varicella-zoster virus infection (picture 8A-C), mpox (monkeypox) infection, and bullous impetigo (picture 9A-B). Maintaining coxsackievirus A6 HFMD in the differential diagnosis of patients thought to have eczema herpeticum may prevent inappropriate antiviral treatment and concern for herpes simplex virus-associated morbidity. (See "Diagnosis of varicella-zoster virus infection" and "Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection", section on 'Eczema herpeticum' and "Epidemiology, clinical manifestations, and diagnosis of mpox (monkeypox)" and "Impetigo", section on 'Bullous impetigo'.)

Treatment and prognosis — Treatment of coxsackievirus A6 HFMD is supportive. Affected children are expected to recover fully without permanent scarring. In children with darker skin types, there is frequently extensive postinflammatory pigmentation that can last months to years but ultimately resolves.

PAPULAR-PURPURIC GLOVES AND SOCKS SYNDROME — Papular-purpuric gloves and socks syndrome (PPGSS) is a distinctive manifestation of parvovirus B19 infection, usually seen in adolescents and adults [46,47]. A juvenile variant that occurs in children has also been described [48].

As the name implies, there is a striking acral distribution of the rash, in contrast to the "slapped cheek" appearance of erythema infectiosum, the better recognized manifestation of parvovirus B19 infection in young children. (See "Clinical manifestations and diagnosis of parvovirus B19 infection", section on 'Erythema infectiosum'.)

PPGSS usually occurs in the spring and summer and has occasionally been linked with etiologic agents other than B19 [49-51]. Transmission occurs through respiratory secretions and saliva. Infected patients are most contagious during the phase of active viral replication, which usually precedes the appearance of skin lesions. (See "Virology, epidemiology, and pathogenesis of parvovirus B19 infection".)

Clinical manifestations — PPGSS is often preceded by prodromal symptoms including low-grade fever, myalgias, arthralgias, and fatigue. The rash is rapidly progressive, with edema and redness of hands and feet followed by the appearance of petechial and/or purpuric lesions on the palms and soles (picture 10A); the dorsal surfaces may also be involved (picture 10B). There is often a sharp cutoff at the wrists or ankles, although elbows and knees may also be involved. Neurologic symptoms are sometimes associated; lymphadenopathy is common.

Routine laboratory tests are usually normal. Some patients may have lymphopenia, neutropenia, or thrombocytopenia.

Complications of parvovirus B19 infection include transient aplastic crisis (especially in pregnancy or human immunodeficiency virus [HIV] infection), hepatitis, arthritis, and cardiomyopathy. Parvovirus B19 infection is also associated with miscarriages and hydrops fetalis. (See "Clinical manifestations and diagnosis of parvovirus B19 infection" and "Parvovirus B19 infection during pregnancy".)

Diagnosis and differential diagnosis — The diagnosis of PPGSS is usually clinical. In immunocompetent patients, the detection of specific immunoglobulin M (IgM) antibodies in serum samples by enzyme immunoassays can confirm the diagnosis. Detectable levels of B19-specific IgM can be found within 7 to 10 days of virus exposure and remain measurable for several months.

Nucleic acid amplification testing is considered the most sensitive test to detect the virus in serum or tissues and is now available in many clinical laboratories. It is especially useful for the diagnosis of parvovirus B19 infection in immunocompromised patients. (See "Virology, epidemiology, and pathogenesis of parvovirus B19 infection".)

A skin biopsy is not helpful for the diagnosis of PPGSS. Histopathologic findings are nonspecific and include a mild lymphohistiocytic perivascular inflammatory infiltrate, degeneration of basal layer, and red blood cell extravasation.

The differential diagnosis of PPGSS includes meningococcemia (picture 11), Rocky Mountain spotted fever (picture 12), immunoglobulin A (IgA) vasculitis (Henoch-Schönlein purpura) (picture 13), perniosis, acral vasculopathy associated with SARS-CoV-2 virus infection, and other petechial viral exanthems (eg, echovirus, parechovirus). (See "Clinical manifestations of meningococcal infection" and "Clinical manifestations and diagnosis of Rocky Mountain spotted fever" and "IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis" and "COVID-19: Cutaneous manifestations and issues related to dermatologic care".)

Treatment and prognosis — Treatment is symptomatic. Spontaneous resolution occurs in several weeks without sequelae.

SUMMARY AND RECOMMENDATIONS

Unilateral laterothoracic exanthem – Unilateral laterothoracic exanthem, also called asymmetric periflexural exanthem of childhood, is a skin eruption of unknown etiology that typically begins on one side of the trunk and then generalizes (picture 1). The diagnosis is clinical. Spontaneous resolution occurs in several weeks without scarring. (See 'Unilateral laterothoracic exanthem' above.)

Atypical hand, foot, and mouth disease – Outbreaks of atypical hand, foot, and mouth disease (HFMD) caused by coxsackievirus A6 in children and young adults have been reported in Asia and in Europe since 2008 and in the United States since 2011. In contrast with classic HFMD caused by coxsackievirus A16, skin involvement is more extensive and severe (picture 4A). The diagnosis may be confirmed by coxsackievirus A6 nucleotide sequencing in blister fluid. Treatment is supportive; spontaneous resolution occurs in days to weeks. (See 'Atypical hand, foot, and mouth disease' above and "Hand, foot, and mouth disease and herpangina", section on 'Hand, foot, and mouth disease' and "Hand, foot, and mouth disease and herpangina".)

Papular-purpuric gloves and socks syndrome – Papular-purpuric gloves and socks syndrome (PPGSS) is a distinctive manifestation of parvovirus B19 infection, usually seen in adolescents and adults. It presents with edema and redness of hands and feet, followed by the appearance of petechial and/or purpuric lesions on the palms and soles (picture 10A-B). The diagnosis may be confirmed by the detection of specific IgM antibodies in serum samples. Spontaneous resolution occurs in several weeks. (See 'Papular-purpuric gloves and socks syndrome' above.)

  1. Drago F, Paolino S, Rebora A, et al. The challenge of diagnosing atypical exanthems: a clinico-laboratory study. J Am Acad Dermatol 2012; 67:1282.
  2. Chuh A, Zawar V, Law M, Sciallis G. Gianotti-Crosti syndrome, pityriasis rosea, asymmetrical periflexural exanthem, unilateral mediothoracic exanthem, eruptive pseudoangiomatosis, and papular-purpuric gloves and socks syndrome: a brief review and arguments for diagnostic criteria. Infect Dis Rep 2012; 4:e12.
  3. Brandt O, Abeck D, Gianotti R, Burgdorf W. Gianotti-Crosti syndrome. J Am Acad Dermatol 2006; 54:136.
  4. Bodemer C, de Prost Y. Unilateral laterothoracic exanthem in children: a new disease? J Am Acad Dermatol 1992; 27:693.
  5. Bhattacharjee R, Narang T. Unilateral Laterothoracic Exanthema: An Underrecognized, Innocuous Entity. J Cutan Med Surg 2019; 23:97.
  6. Taïeb A, Mégraud F, Legrain V, et al. Asymmetric periflexural exanthem of childhood. J Am Acad Dermatol 1993; 29:391.
  7. Chuh A, Zawar V, Sciallis GF, et al. Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies? Infect Dis Rep 2016; 8:6418.
  8. McCuaig CC, Russo P, Powell J, et al. Unilateral laterothoracic exanthem. A clinicopathologic study of forty-eight patients. J Am Acad Dermatol 1996; 34:979.
  9. Scheinfeld N. Unilateral laterothoracic exanthema with coincident evidence of Epstein Barr virus reactivation: exploration of a possible link. Dermatol Online J 2007; 13:13.
  10. Coustou D, Léauté-Labrèze C, Bioulac-Sage P, et al. Asymmetric periflexural exanthem of childhood: a clinical, pathologic, and epidemiologic prospective study. Arch Dermatol 1999; 135:799.
  11. Chamli A, Souissi A, Midassi O, Mokni M. Unilateral laterothoracic exanthema in an adult. Clin Case Rep 2020; 8:3294.
  12. Duarte AF, Cruz MJ, Baudrier T, et al. Unilateral laterothoracic exanthem and primary Epstein-Barr virus infection: case report. Pediatr Infect Dis J 2009; 28:549.
  13. Glick LR, Fogel AL, Ramachandran S, Barakat LA. Unilateral laterothoracic exanthem in association with coronavirus disease 2019. JAAD Case Rep 2020; 6:900.
  14. Chuh A. Asymmetric periflexural/unilateral laterothoracic exanthem related to parvovirus B19 infection: An adult carrier of ß-globin thalassaemia gene mutation in Hong Kong. Australas J Dermatol 2016; 57:e141.
  15. Guimerá-Martín-Neda F, Fagundo E, Rodríguez F, et al. Asymmetric periflexural exanthem of childhood: report of two cases with parvovirus B19. J Eur Acad Dermatol Venereol 2006; 20:461.
  16. Coustou D, Masquelier B, Lafon ME, et al. Asymmetric periflexural exanthem of childhood: microbiologic case-control study. Pediatr Dermatol 2000; 17:169.
  17. Gelmetti C, Caputo R. Asymmetric periflexural exanthem of childhood: who are you? J Eur Acad Dermatol Venereol 2001; 15:293.
  18. Prose NS, Tope W, Miller SE, Kamino H. Eruptive pseudoangiomatosis: a unique childhood exanthem? J Am Acad Dermatol 1993; 29:857.
  19. Hoeger PH, Colmenero I. Vascular tumours in infants. Part I: benign vascular tumours other than infantile haemangioma. Br J Dermatol 2014; 171:466.
  20. Neri I, Patrizi A, Guerrini V, Badiali L. A new case of eruptive pseudoangiomatosis: ultrastructural study. J Eur Acad Dermatol Venereol 2004; 18:387.
  21. Kim JE, Kim BJ, Park HJ, et al. Clinicopathologic review of eruptive pseudoangiomatosis in Korean adults: report of 32 cases. Int J Dermatol 2013; 52:41.
  22. Yang JH, Kim JW, Park HS, et al. Eruptive pseudoangiomatosis. J Dermatol 2006; 33:873.
  23. Venturi C, Zendri E, Medici MC, et al. Eruptive pseudoangiomatosis in adults: a community outbreak. Arch Dermatol 2004; 140:757.
  24. González Saldaña S, Mendez Flores RG, López Gutiérrez AF, et al. Eruptive pseudoangiomatosis in adults with immune system disorders: A report of two cases. Dermatol Reports 2020; 12:8836.
  25. Oka K, Ohtaki N, Kasai S, et al. Two cases of eruptive pseudoangiomatosis induced by mosquito bites. J Dermatol 2012; 39:301.
  26. Pitarch G, Torrijos A, García-Escrivá D, Martínez-Menchón T. Eruptive pseudoangiomatosis associated to cytomegalovirus infection. Eur J Dermatol 2007; 17:455.
  27. Cherry JD, Bobinski JE, Horvath FL, Comerci GD. Acute hemangioma-like lesions associated with ECHO viral infections. Pediatrics 1969; 44:498.
  28. Larralde M, Ballona R, Correa N, et al. Eruptive pseudoangiomatosis. Pediatr Dermatol 2002; 19:76.
  29. Navarro V, Molina I, Montesinos E, et al. Eruptive pseudoangiomatosis in an adult. Int J Dermatol 2000; 39:237.
  30. Chuh A, Panzer R, Rosenthal AC, et al. Annular Eruptive Pseudoangiomatosis and Adenovirus Infection: A Novel Clinical Variant of Paraviral Exanthems and a Novel Virus Association. Acta Derm Venereol 2017; 97:354.
  31. Wambier CG, Cappel MA, Danilau Ostroski TK, et al. Familial outbreak of eruptive pseudoangiomatosis with dermoscopic and histopathologic correlation. J Am Acad Dermatol 2017; 76:S12.
  32. Rivas-Calderón MK, Morán-Villaseñor E, Maza-Ramos G, et al. Eruptive pseudoangiomatosis in two children with acute lymphoblastic leukemia. Int J Dermatol 2018; 57:e38.
  33. Alonzo Caldarelli A, Barba P, Hurtado M. Eruptive pseudoangiomatosis and SARS-CoV-2 (COVID-19) infection. Int J Dermatol 2021; 60:1028.
  34. Chopra D, Sharma A, Kaur S, Singh R. Eruptive pseudoangiomatosis - cherry angiomas with perilesional halo. Indian J Dermatol Venereol Leprol 2018; 84:424.
  35. Angelo C, Provini A, Ferranti G, et al. Eruptive pseudoangiomatosis. Pediatr Dermatol 2002; 19:243.
  36. Centers for Disease Control and Prevention (CDC). Notes from the field: severe hand, foot, and mouth disease associated with coxsackievirus A6 - Alabama, Connecticut, California, and Nevada, November 2011-February 2012. MMWR Morb Mortal Wkly Rep 2012; 61:213.
  37. Feder HM Jr, Bennett N, Modlin JF. Atypical hand, foot, and mouth disease: a vesiculobullous eruption caused by Coxsackie virus A6. Lancet Infect Dis 2014; 14:83.
  38. Han JF, Xu S, Zhang Y, et al. Hand, foot, and mouth disease outbreak caused by coxsackievirus A6, China, 2013. J Infect 2014; 69:303.
  39. Buttery VW, Kenyon C, Grunewald S, et al. Atypical Presentations of Hand, Foot, and Mouth Disease Caused by Coxsackievirus A6--Minnesota, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:805.
  40. Xu S, Li H, Qiao P, et al. Neonatal hand, foot, and mouth disease due to coxsackievirus A6 in Shanghai. BMC Pediatr 2020; 20:364.
  41. Ben-Chetrit E, Wiener-Well Y, Shulman LM, et al. Coxsackievirus A6-related hand foot and mouth disease: skin manifestations in a cluster of adult patients. J Clin Virol 2014; 59:201.
  42. Banta J, Lenz B, Pawlak M, et al. Notes from the Field: Outbreak of Hand, Foot, and Mouth Disease Caused by Coxsackievirus A6 Among Basic Military Trainees - Texas, 2015. MMWR Morb Mortal Wkly Rep 2016; 65:678.
  43. Andreoni AR, Colton AS. Coxsackievirus B5 associated with hand-foot-mouth disease in a healthy adult. JAAD Case Rep 2017; 3:165.
  44. Mathes EF, Oza V, Frieden IJ, et al. "Eczema coxsackium" and unusual cutaneous findings in an enterovirus outbreak. Pediatrics 2013; 132:e149.
  45. Hubiche T, Schuffenecker I, Boralevi F, et al. Dermatological spectrum of hand, foot and mouth disease from classical to generalized exanthema. Pediatr Infect Dis J 2014; 33:e92.
  46. Gutermuth J, Nadas K, Zirbs M, et al. Papular-purpuric gloves and socks syndrome. Lancet 2011; 378:198.
  47. Mage V, Lipsker D, Barbarot S, et al. Different patterns of skin manifestations associated with parvovirus B19 primary infection in adults. J Am Acad Dermatol 2014; 71:62.
  48. Hsieh MY, Huang PH. The juvenile variant of papular-purpuric gloves and socks syndrome and its association with viral infections. Br J Dermatol 2004; 151:201.
  49. Santonja C, Nieto-González G, Santos-Briz Á, et al. Immunohistochemical detection of parvovirus B19 in "gloves and socks" papular purpuric syndrome: direct evidence for viral endothelial involvement. Report of three cases and review of the literature. Am J Dermatopathol 2011; 33:790.
  50. Pemira SM, Tolan RW Jr. Mycoplasma pneumoniae infection presenting as bullous papular purpuric gloves and socks syndrome: novel association and review of the literature. Clin Pediatr (Phila) 2011; 50:1140.
  51. Kappers W, Stevens G, Bruynseels P, van den Akker M. Papular Purpuric Gloves and Socks Syndrome because of a Mycoplasma Infection. J Pediatr 2018; 194:258.
Topic 13739 Version 15.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟